Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 10Other neoplasm 4Breast 4Head & Neck 3Tumor-Agnostic 1Thoracic 1Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Dermatologic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 2Neoplasms 1Leukoplakia, Oral 1Coproporphyria 1

Interventions

Cisplatin 631Radiotherapy 339pembrolizumab 329Cetuximab 284Docetaxel 226Radiotherapy, Intensity-Modulated 221Fluorouracil 199Carboplatin 198Paclitaxel 161Nivolumab 145Gemcitabine 125Magnetic Resonance Spectroscopy 99Radiation 91Drug Therapy 86Capecitabine 77toripalimab 75Surveys and Questionnaires 73Surgical Procedures, Operative 72Biopsy 62durvalumab 61Chemoradiotherapy 52Blood Specimen Collection 52Cyclophosphamide 50Specimen Handling 47camrelizumab 46Radiosurgery 46Erlotinib Hydrochloride 46Standard of Care 44130-nm albumin-bound paclitaxel 44tislelizumab 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Sulindac × Head & Neck × Clear all
NCT01515137 2023-03-28

Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma

University of Pittsburgh

Phase 1 Completed
47 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT00299195 2020-11-19

A Randomized Study of Sulindac in Oral Premalignant Lesions

Memorial Sloan Kettering Cancer Center

Phase NA Completed
63 enrolled 10 charts
Head & Neck

Coproporphyria, Leukoplakia, Oral, Neoplasms

NCT00392665 2017-04-13

Bevacizumab/Tarceva and Tarceva/Sulindac in Squamous Cell Carcinoma of the Head and Neck

Massachusetts General Hospital

Phase 2 Terminated
36 enrolled 10 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

Data powered by HemOnc (CC BY 4.0) Colophon âš¡